journal article·2026-07

Dismantling the Stromal‐Metabolic Barrier in TNBC via Machine Learning‐Guided Pan‐Immune Activity Nano‐Regulator

Xinyu Xiang, Letian Lv, Shanyi Lin, Xiaofeng Zhu, Haochen Yao, Lingxiao Zhang, Shuilin Wu, Shixian Lv, Yamei Miao, Kaiyang Wang, Yu Luo

Advanced Functional Materials· Volume 36· Issue 57
Publisher page

Abstract

ABSTRACT Triple‐negative breast cancer establishes a stromal‐metabolic barrier, characterized by dense fibrosis and metabolic dysregulation, to induce immunotherapy resistance. To dismantle this barrier, we propose a P rogrammable R ewiring of I mmuno‐ S tromal M etabolism ( PRISM ) strategy, supported by a POD‐like activity‐oriented machine learning (ML) screening of representative catalytic metals. A metabolic nanoregulator, Au@Fe–Co@HA (ACFH), was engineered to couple glucose starvation with Fe/Co‐mediated oxidative therapy. The Au core of ACFH acted as a glucose oxidase‐like enzyme to deplete glucose and generate endogenous H 2 O 2 , thereby powering the peroxidase‐like activity of the iron‐cobalt (Fe/Co) shell. In vivo, ACFH‐mediated combined therapy reduced GLUT1 expression in tumor tissues and suppressed glucose uptake and glycolysis‐associated metabolic activity. The GSH‐responsive release of Fe/Co ions disrupted redox homeostasis and activated immunogenic cell death (ICD), facilitating dendritic cell maturation, M1 macrophage polarization, and CD4 + /CD8 + T‐cell infiltration. When combined with immune checkpoint blockade, the therapeutic efficacy was further enhanced. In this study, ML was used to translate the therapeutic requirement for ROS‐amplified ferroptosis and immunogenic therapy into a quantifiable catalytic screening endpoint. By integrating this function‐oriented metal selection with the PRISM strategy, this work provides a rational nanoregulator design to overcome stromal‐metabolic resistance in TNBC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Ferroptosis and cancer prognosis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shanghai Engineering Research Center of Pharmaceutical Intelligent Equipment Shanghai Frontiers Science Research Center For Druggability of Cardiovascular Non‐Coding RNA Institute For Frontier Medical Technology School of Chemistry and Chemical Engineering Shanghai University of Engineering Science Shanghai P. R. China

School of Materials Science and Engineering Peking University Beijing P. R. China

Key Laboratory and Engineering Laboratory of Lymphatic Surgery Jilin Province China‐Japan Union Hospital of Jilin University Changchun Jilin P. R. China

Interdisciplinary Nanoscience Center (INANO) Aarhus University Aarhus Denmark

Funding

National Natural Science Foundation of China

References (35)

Show source-provided references
1. 10.1186/s13045‐025‐01736‐910.1186/s13045‐025‐01736‐9 ↗
2. 10.1038/s41422‐023‐00909‐w10.1038/s41422‐023‐00909‐w ↗
3. 10.1016/j.cmet.2022.09.02110.1016/j.cmet.2022.09.021 ↗
4. 10.1038/s41586‐025‐09903‐110.1038/s41586‐025‐09903‐1 ↗
5. 10.1016/j.ccell.2025.01.00710.1016/j.ccell.2025.01.007 ↗
6. 10.1038/s41467-023-42883-210.1038/s41467-023-42883-2 ↗
7. 10.1002/cac2.1229110.1002/cac2.12291 ↗
8. 10.1016/j.ebiom.2019.02.02510.1016/j.ebiom.2019.02.025 ↗
9. 10.1016/j.scib.2025.05.02910.1016/j.scib.2025.05.029 ↗
10. 10.1016/j.cmet.2018.08.00710.1016/j.cmet.2018.08.007 ↗
11. 10.1002/adfm.20221251010.1002/adfm.202212510 ↗
12. 10.1158/0008‐5472.CAN‐23‐039810.1158/0008‐5472.CAN‐23‐0398 ↗
13. 10.1038/s41467-024-49282-110.1038/s41467-024-49282-1 ↗
14. 10.1038/s41467‐018‐03347‐010.1038/s41467‐018‐03347‐0 ↗
15. 10.1186/s12943‐019‐0994‐210.1186/s12943‐019‐0994‐2 ↗
16. 10.1038/s41467-023-40850-510.1038/s41467-023-40850-5 ↗
17. 10.1186/s12943‐023‐01731‐z10.1186/s12943‐023‐01731‐z ↗
18. 10.1186/s13045‐024‐01600‐210.1186/s13045‐024‐01600‐2 ↗
19. 10.1038/s41392‐020‐00449‐410.1038/s41392‐020‐00449‐4 ↗
20. 10.1038/s41568‐019‐0238‐110.1038/s41568‐019‐0238‐1 ↗
21. 10.1039/D1CS00609F10.1039/D1CS00609F ↗
22. 10.1016/j.ccr.2023.21553510.1016/j.ccr.2023.215535 ↗
23. 10.1016/j.biomaterials.2025.12312610.1016/j.biomaterials.2025.123126 ↗
24. 10.1158/2159‐8290.CD‐19‐076110.1158/2159‐8290.CD‐19‐0761 ↗
25. 10.1016/j.ccell.2024.03.01110.1016/j.ccell.2024.03.011 ↗
26. 10.1002/adfm.20240202210.1002/adfm.202402022 ↗
27. 10.1002/adma.20190419710.1002/adma.201904197 ↗
28. 10.1002/adfm.20211178410.1002/adfm.202111784 ↗
29. 10.1016/j.nantod.2023.10189610.1016/j.nantod.2023.101896 ↗
30. 10.1038/s41590‐020‐0699‐010.1038/s41590‐020‐0699‐0 ↗
31. 10.2147/IJN.S35514210.2147/IJN.S355142 ↗
32. 10.1039/D0CS01121E10.1039/D0CS01121E ↗
33. 10.1021/jacs.3c1358810.1021/jacs.3c13588 ↗
34. 10.1126/sciadv.aba077610.1126/sciadv.aba0776 ↗
35. 10.1038/s12276‐023‐01013‐010.1038/s12276‐023‐01013‐0 ↗